{"id":3016,"date":"2018-07-02T08:59:04","date_gmt":"2018-07-02T12:59:04","guid":{"rendered":"http:\/\/www.drugpatentwatch.com\/blog\/?p=3016"},"modified":"2026-03-30T19:02:35","modified_gmt":"2026-03-30T23:02:35","slug":"biosimilars-in-developed-and-developing-east-and-southeast-asian-countries-japan-south-korea-and-malaysia-overview-evolution-and-regulations-assessment","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/biosimilars-in-developed-and-developing-east-and-southeast-asian-countries-japan-south-korea-and-malaysia-overview-evolution-and-regulations-assessment\/","title":{"rendered":"Asia’s Biosimilar Market: Japan, South Korea & Malaysia – The Definitive IP, Regulatory, and Commercial Strategy Guide"},"content":{"rendered":"\n

Why Asia is the New Biosimilar Battleground<\/strong><\/h2>\n\n\n\n

The Patent Cliff Meets a Demographic Supercycle<\/strong><\/h3>\n\n\n\n
\"\"<\/figure>\n\n\n\n

The most consequential commercial event in biopharma over the next decade is not a drug approval or a clinical trial readout. It is the convergence of two slow-moving structural forces: the patent expiration of the world’s highest-revenue biologics and the accelerating healthcare demand driven by aging populations across East and Southeast Asia.<\/p>\n\n\n\n

Between 2025 and 2032, biologics generating a combined estimated $200 billion in annual global revenue face patent cliffs. The list includes Humira (adalimumab), Stelara (ustekinumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Eylea (aflibercept), and the entire oncology immunotherapy stack that reshaped medicine over the past fifteen years. Each of these molecules is protected not by a single patent but by layered intellectual property portfolios, and the precise shape of each cliff — when it starts, how steep it is, and in which jurisdiction it occurs first — differs materially by country.<\/p>\n\n\n\n

Japan, South Korea, and Malaysia occupy distinct positions in this commercial landscape. Japan, the world’s third-largest pharmaceutical market at roughly $90 billion in annual drug spend, offers the highest realized revenue per approved product but runs one of the most counterintuitive reimbursement systems in the world. South Korea, with an estimated $22 billion biopharma market, has transformed itself through deliberate state capitalism into the second-most prolific source of FDA-approved biosimilars globally, behind only the United States itself. Malaysia, a $900 million combined generic-and-biosimilar market growing at a steady 4% CAGR, is at a structural inflection point: regulation is mature, procurement is broken, and the gap between those two facts is both the central challenge and the central opportunity.<\/p>\n\n\n\n

This guide provides the granular technical, regulatory, IP, and commercial intelligence needed to build a winning strategy in each arena.<\/p>\n\n\n\n

\n\n\n\n

Part I — The Biosimilar Blueprint: Science, Manufacturing, and IP Creation<\/strong><\/h2>\n\n\n\n

What a Biosimilar Is (and Isn’t)<\/strong><\/h3>\n\n\n\n

The ‘Similar, Not Identical’ Standard and Why It Matters for IP<\/strong><\/h4>\n\n\n\n

A biosimilar is a biological medicine approved on the basis that it is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. The FDA, EMA, PMDA, MFDS, and NPRA are aligned on this definition, even as their specific evidentiary requirements diverge in the details.<\/p>\n\n\n\n

The word ‘similar’ is not a regulatory hedge. It reflects a hard scientific reality. Biologics are produced in living cell systems — most commonly Chinese Hamster Ovary (CHO) cells for mammalian-expressed proteins, or Escherichia coli<\/em> and Saccharomyces cerevisiae<\/em> for simpler structures. No two cell lines, even those expressing the same coding sequence, produce an identical glycoprotein profile. Post-translational modifications, principally N-linked and O-linked glycosylation, are a function of the host cell’s metabolic state, the bioreactor feeding strategy, dissolved oxygen tension, and dozens of other process variables. The originator’s glycan profile is itself a moving target across manufacturing batches, within approved specification limits.<\/p>\n\n\n\n

This fact has a direct and underappreciated IP consequence. Because the originator cannot patent a molecule per se — only specific compositions, formulations, methods of manufacture, and methods of use — the biosimilar developer’s task is to reverse-engineer a process that reliably produces a glycoprotein population sufficiently similar to the reference product’s approved specification range, without infringing any active patent claims covering the originator’s specific process. The process is the product, and the process is also the IP asset.<\/p>\n\n\n\n

Why the Generic Drug Analogy Fails Strategically<\/strong><\/h4>\n\n\n\n

The generic drug development model is instructive mainly for understanding what biosimilar development is not. A generic developer synthesizes an identical small-molecule active pharmaceutical ingredient (API), runs a single-dose crossover pharmacokinetic study in 24 to 36 healthy volunteers to demonstrate bioequivalence, and files an Abbreviated New Drug Application (ANDA) at a total development cost typically between $1 million and $4 million over roughly 24 months.<\/p>\n\n\n\n

Biosimilar development runs $100 million to $250 million over seven to nine years. The capital requirement for a state-of-the-art commercial-scale biomanufacturing facility — typically requiring 10,000 to 20,000 liters of bioreactor capacity for a high-volume monoclonal antibody — exceeds $500 million. The supply chain requires an unbroken cold chain at 2-8 degrees Celsius from fill-finish to patient administration, adding logistical costs that have no analog in the oral solid dosage world. Protein degradation pathways — aggregation, deamidation, oxidation, fragmentation — require rigorous stability programs across multiple climatic zones, each with distinct temperature and humidity stress profiles.<\/p>\n\n\n\n

These cost and complexity differences produce a structurally different competitive market. Generics attract dozens of filers once a molecule goes off-patent, driving rapid price erosion to near-commodity levels. Biosimilars attract a handful of well-capitalized developers per molecule, creating an oligopolistic structure where even a 20-30% price discount over the originator can yield enormous revenue. The market for a leading biosimilar position against a $6 billion annual revenue reference product can be worth $500 million to $1 billion in net revenue, even after accounting for price erosion. That math explains why Pfizer, Amgen, Sandoz, Celltrion, and Samsung Bioepis compete at the same level.<\/p>\n\n\n\n

\n\n\n\n

The Manufacturing Stack: Where IP Is Born<\/strong><\/h3>\n\n\n\n

Cell Line Development and the Proprietary Master Cell Bank<\/strong><\/h4>\n\n\n\n

The starting point of any biomanufacturing program is cell line development. The developer must generate a new, proprietary cell line — the originator’s cell line is a trade secret and a core competitive asset, never disclosed in regulatory filings or published literature. This requires transfecting the coding sequence for the desired protein into a CHO host cell, selecting high-producing clones through a multi-round screening process, and banking the final clone as a Master Cell Bank (MCB) and Working Cell Bank (WCB).<\/p>\n\n\n\n

Cell line selection criteria include volumetric productivity (grams of protein per liter of culture per day), product quality attributes (specifically the glycosylation profile), genetic stability over the cell passages that correspond to a commercial manufacturing campaign, and absence of adventitious agents. The MCB is a regulated starting material, and its characterization package — full genomic sequencing, adventitious agent testing, expression level documentation — is submitted as part of the biosimilar’s quality dossier to every regulatory authority.<\/p>\n\n\n\n

The cell line itself is potentially patentable. CHO expression systems developed for specific proteins can be covered by patents on the cell line’s genetic modifications, the selection marker systems used, or the fed-batch media compositions that drive productivity. A freedom-to-operate analysis for any biosimilar program must include a sweep of cell line patents, not just product and process patents.<\/p>\n\n\n\n

Upstream Bioprocess: Fed-Batch, Perfusion, and the Scale-Up Challenge<\/strong><\/h4>\n\n\n\n

Commercial biomanufacturing uses either fed-batch or perfusion culture modes. Fed-batch, the dominant paradigm for monoclonal antibody production, involves inoculating a bioreactor with cells from the working cell bank, growing the culture to peak cell density over 10 to 14 days with sequential nutrient additions, then harvesting the culture fluid. Titers for commercial-scale mAb production routinely reach 5 to 10 grams per liter in leading operations, a ten-fold improvement over early 2000s benchmarks driven primarily by media and feeding strategy optimization.<\/p>\n\n\n\n

Perfusion culture, increasingly adopted for products requiring shorter culture durations or for intensified processes that increase annual facility output, involves continuous cell retention and fresh media addition. Perfusion creates a different glycoprotein environment — lower ammonia accumulation, more consistent pH and dissolved oxygen — which can shift glycosylation profiles relative to fed-batch production of the same protein. A biosimilar developer switching from fed-batch to perfusion must demonstrate that the resulting product quality attributes remain within the analytical similarity range established against the reference product.<\/p>\n\n\n\n

Scale-up from bench (2-liter bioreactor) to clinical manufacturing (200 to 500 liters) to commercial scale (10,000 to 20,000 liters) is not linear. Mixing efficiency, dissolved oxygen gradients, shear stress on cells, and heat transfer all change non-linearly with vessel volume. Each scale change can alter glycosylation patterns, aggregation propensity, and charge heterogeneity. The manufacturing process validation package submitted to regulators must demonstrate consistency across at least three full-scale commercial batches.<\/p>\n\n\n\n

Downstream Purification: Chromatography Trains and the Purity Imperative<\/strong><\/h4>\n\n\n\n

Downstream processing purifies the target protein from host cell proteins (HCPs), host cell DNA, product-related impurities (aggregates, fragments, charge variants), and process-related impurities (Protein A leachate, viral particles). A standard mAb purification train includes a Protein A affinity capture step, two orthogonal polishing chromatography steps (typically ion exchange and hydrophobic interaction or mixed-mode), and viral clearance steps including low-pH hold and nanofiltration.<\/p>\n\n\n\n

Each chromatography resin, membrane, and buffer system is potentially covered by vendor patents. More critically, the specific configuration of steps, the operating conditions (pH, conductivity, gradient slopes), and the pooling criteria that define a ‘good’ fraction are proprietary process knowledge. A biosimilar developer cannot access the originator’s purification train specifications. The developer must build a process that consistently achieves purity specifications — typically less than 100 ppm HCP, undetectable host cell DNA, and aggregation below 1-2% by size exclusion chromatography — that match the reference product’s profile, using methods that do not infringe active process patents.<\/p>\n\n\n\n

The Glycosylation Similarity Standard: What Regulators Require<\/strong><\/h4>\n\n\n\n

Glycosylation is the most scrutinized post-translational modification in biosimilar comparability exercises. For IgG1 monoclonal antibodies, the Fc glycan at Asn297 directly regulates antibody-dependent cellular cytotoxicity (ADCC) activity through its interaction with Fc gamma receptors on natural killer cells and macrophages. Afucosylated glycoforms enhance ADCC; high-mannose glycoforms accelerate clearance.<\/p>\n\n\n\n

Regulators require a complete N-glycan profiling comparison between biosimilar and reference product using methods including normal-phase HPLC with fluorescence detection, capillary electrophoresis with laser-induced fluorescence (CE-LIF), and high-resolution mass spectrometry (LC-MS\/MS). The specification ranges for major glycoforms (G0F, G1F, G2F, and their afucosylated counterparts) must be defined and shown to overlap with the reference product’s distribution. If a biosimilar’s fucosylation level differs materially from the reference product, the developer must present functional ADCC data to demonstrate no clinically meaningful difference.<\/p>\n\n\n\n

\n\n\n\n

The Global Regulatory Comparability Exercise<\/strong><\/h3>\n\n\n\n

The Totality-of-Evidence Pyramid<\/strong><\/h4>\n\n\n\n

The regulatory approval of a biosimilar rests on a stepwise comparability exercise governed by the ‘totality of the evidence’ principle. The logical architecture is a three-tier pyramid: a broad, deep base of analytical chemistry data, a middle tier of non-clinical functional data, and a narrow peak of targeted clinical confirmation. The strength of the lower tiers reduces the data requirements at the upper tiers — a principle that, properly executed, saves hundreds of millions in development cost and years of development time.<\/p>\n\n\n\n

The base tier covers primary structure (amino acid sequence by peptide mapping with MS confirmation), higher-order structure (secondary structure by circular dichroism and FTIR, tertiary structure by near-UV CD and intrinsic fluorescence, quaternary interactions by analytical ultracentrifugation), post-translational modifications (N- and O-glycan profiling, disulfide bond mapping, methionine oxidation, asparagine deamidation), biological activity (receptor binding affinity by SPR and ELISA, Fc effector function assays, cell-based potency), and impurity profile (aggregates, fragments, HCPs, DNA).<\/p>\n\n\n\n

The middle tier uses in vitro cell-based assays and, where required by specific product risk profiles, comparative in vivo pharmacology and toxicology studies in relevant animal species. The value of in vivo non-clinical studies for mAbs is limited, since most rodent models do not express the human antigen target. Regulators, including the PMDA and MFDS, are increasingly willing to waive repeated-dose toxicology studies when the quality data is analytically compelling and no new safety signals are anticipated.<\/p>\n\n\n\n

The peak tier is clinical confirmation: a comparative pharmacokinetic study, typically a single-dose crossover design in healthy volunteers, using both intravenous and subcutaneous routes if both are commercially relevant, followed by a comparative pharmacodynamic endpoint study if a validated PD biomarker exists. A large-scale equivalence trial in patients — the most expensive element — is required only when residual uncertainty about clinical comparability cannot be resolved through the analytical and PK\/PD evidence alone.<\/p>\n\n\n\n

Extrapolation: The Commercial Multiplier<\/strong><\/h4>\n\n\n\n

Extrapolation is the regulatory principle that allows a biosimilar approved in one indication to receive approval in all other indications of the reference product, without requiring separate clinical trials for each one. It is not automatic and requires scientific justification, but when granted, it multiplies the commercial value of a single clinical development program by the number of approved indications.<\/p>\n\n\n\n

The standard justification for extrapolation includes: the mechanism of action is the same across all extrapolated indications; the safety and efficacy profile is adequately characterized in the tested population; and there are no specific patient or disease factors in the extrapolated indications that would create meaningful uncertainty about the comparable performance of the biosimilar.<\/p>\n\n\n\n

For rituximab, which has approved indications in non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris, a biosimilar developer that runs a single comparative PK study and an efficacy confirmation trial in one oncology indication can potentially receive approval across all six. The development cost savings from extrapolation for a multi-indication product can reach $200 million or more.<\/p>\n\n\n\n

Biosimilar Interchangeability: A Critical Commercial Distinction<\/strong><\/h4>\n\n\n\n

Interchangeability designations differ materially across the jurisdictions covered in this guide, and the commercial implications of those differences are substantial.<\/p>\n\n\n\n

In the United States, the FDA grants ‘interchangeable’ status as a specific, higher designation under the Biologics Price Competition and Innovation Act (BPCIA). An interchangeable biosimilar has demonstrated, typically through a switching study alternating patients between biosimilar and reference product, that it produces the same clinical result and that switching does not carry an increased risk of adverse events or diminished efficacy. This designation permits pharmacy-level automatic substitution without prescriber consultation, the pharmacist behavior that drives rapid generic substitution rates of 80-90% in the small-molecule world. As of early 2026, the FDA has granted interchangeable designation to a small but growing number of biosimilars, including several insulins and an adalimumab biosimilar.<\/p>\n\n\n\n

In the European Union, the EMA’s official scientific position, shared by the Heads of Medicines Agencies (HMA), is that all EMA-approved biosimilars are interchangeable, meaning a prescriber can switch a patient from reference product to biosimilar with confidence. The decision on automatic pharmacy substitution is delegated to individual member states, producing a patchwork of national policies. Germany, France, and several Nordic countries permit or encourage substitution under defined conditions; others do not.<\/p>\n\n\n\n

Japan and South Korea have no formal interchangeability designation. Switching is a physician decision, and pharmacist-level substitution is not permitted in either country. Malaysia’s NPRA states that registered biosimilars are interchangeable for prescribing purposes — meaning a physician can choose either product — but explicitly prohibits automatic substitution, and requires all biologics to be prescribed by brand name to ensure traceability.<\/p>\n\n\n\n

The practical commercial implication for any biosimilar developer entering these Asian markets: market share gains depend on changing physician prescribing behavior, not on pharmacy channel dynamics. That requires a medical affairs strategy, real-world evidence generation, and direct engagement with hospital formulary committees, not a pharmacy-focused sales model.<\/p>\n\n\n\n

\n\n\n\n

IP Valuation Framework: Reference Product Patents and Their Commercial Weight<\/strong><\/h3>\n\n\n\n

How to Value a Biosimilar Entry Opportunity<\/strong><\/h4>\n\n\n\n

The risk-adjusted commercial value of a biosimilar program is a function of five variables: reference product revenue in the target market, the expected biosimilar price discount relative to the originator, the achievable market share given the competitive and reimbursement environment, the net present value of development costs discounted for probability of technical and regulatory success, and the probability-weighted legal cost and delay risk from patent litigation.<\/p>\n\n\n\n

Each of these inputs varies substantially by molecule and by country. A trastuzumab biosimilar in Japan generates very different economics than the same product in South Korea, because the reimbursement mechanics, competitive intensity, and patent landscape differ materially. The framework presented below applies to each major molecule discussed in this guide.<\/p>\n\n\n\n

Trastuzumab (Herceptin): The Anchor Oncology Asset<\/strong><\/h4>\n\n\n\n

Herceptin, Genentech\/Roche’s HER2-targeted monoclonal antibody, generated peak global revenues exceeding $6.5 billion annually before biosimilar competition began in earnest. In Japan, trastuzumab biosimilars have been the primary driver of oncology biosimilar adoption, accelerated by the government’s targeted prescribing incentive of roughly 1,500 yen per prescription during the initial post-launch period.<\/p>\n\n\n\n

The trastuzumab patent estate illustrates the full complexity of originator IP strategy. Roche’s primary composition-of-matter patent on the humanized anti-HER2 antibody expired in the early 2010s. However, the company filed and prosecuted downstream patents covering specific formulations (the L-histidine buffered, polysorbate 20-containing lyophilized product), the subcutaneous formulation co-administered with recombinant human hyaluronidase (Herceptin Hylecta), manufacturing process improvements, and device patents covering the single-use injection device for the subcutaneous presentation.<\/p>\n\n\n\n

The subcutaneous formulation represents classic evergreening: a genuinely improved product that extends the commercial life of the franchise by offering patient and nurse convenience, simultaneously creating new IP that the biosimilar developer must design around or wait to expire. Any biosimilar developer filing for the intravenous formulation must still independently develop a subcutaneous variant if they want to capture that growing market segment, and must navigate the device patents separately. This is not unique to trastuzumab — it is a template that originator companies apply systematically to their entire biologic portfolios.<\/p>\n\n\n\n

For IP valuation purposes, the remaining value in the trastuzumab franchise by market is modest, since competitive biosimilar markets are already established in all three Asian markets. The more important analytical exercise is to use trastuzumab as a proof-of-concept for understanding how evergreening will extend the franchise value of next-generation assets like pembrolizumab and aflibercept, which are still years from their primary patent cliffs.<\/p>\n\n\n\n

Bevacizumab (Avastin): The Oncology Workhorse<\/strong><\/h4>\n\n\n\n

Avastin, Genentech\/Roche’s anti-VEGF antibody for colorectal, lung, and cervical cancers, among others, generated peak revenues of roughly $7 billion globally. Bevacizumab biosimilars have penetrated major markets aggressively following the expiration of core composition-of-matter patents. In Japan, bevacizumab biosimilars are among the most actively prescribed, largely because their use is concentrated in the DPC inpatient hospital setting, where the fixed per-diem reimbursement creates a direct financial incentive for hospitals to substitute cheaper alternatives.<\/p>\n\n\n\n

The bevacizumab estate is relatively thin compared to trastuzumab. Roche did not develop a subcutaneous formulation or a combination product that would anchor new IP claims. The primary formulation patent covering the specific buffer and concentration used in Avastin is the main ongoing litigation target. Freedom-to-operate analysis for bevacizumab biosimilar developers centers on demonstrating a different excipient system or buffer composition that achieves equivalent stability and delivers equivalent PK without infringing the specific formulation claims.<\/p>\n\n\n\n

Bevacizumab also has an important ophthalmology use, specifically the off-label treatment of neovascular age-related macular degeneration, a practice that has created a separate market dynamic with its own IP considerations (including Genentech’s separately commercialized Lucentis\/ranibizumab and the newer Eylea\/aflibercept, both still under active patent protection in most Asian markets).<\/p>\n\n\n\n

Adalimumab (Humira): The Global Evergreening Masterclass<\/strong><\/h4>\n\n\n\n

Humira, AbbVie’s anti-TNF-alpha antibody, is the best-documented case study in biological product life cycle management. At peak, it generated more than $20 billion in annual global revenue. AbbVie built a patent portfolio of over 250 patents covering the adalimumab molecule and product, a strategy that delayed biosimilar entry in the United States until 2023, nearly a decade after European biosimilar entry began.<\/p>\n\n\n\n

The AbbVie IP strategy for Humira used every available tool. The core composition-of-matter patents on the fully human anti-TNF antibody and its antigen-binding sequences were filed in the 1990s. AbbVie then filed patents covering: the high-concentration subcutaneous formulation (100 mg\/mL, which produces less injection site pain than the original 50 mg\/mL formulation); citrate-free formulations; specific methods of treating rheumatoid arthritis, psoriasis, and Crohn’s disease; combination uses with methotrexate; manufacturing process improvements including specific purification steps; and the auto-injector device design.<\/p>\n\n\n\n

The high-concentration, citrate-free formulation is particularly instructive for the Asian market context. AbbVie launched this improved formulation across major markets, including Japan, as the standard of care product while the original 50 mg\/mL formulation was the reference used in biosimilar comparability exercises. Biosimilar developers must show similarity to the approved reference product, but if the market has shifted to the improved formulation, commercial success requires matching that formulation’s performance regardless of whether it is the official regulatory reference product. This creates a significant additional development burden.<\/p>\n\n\n\n

In Japan, the adalimumab biosimilar market is active, with products from multiple developers including Daiichi Sankyo, Mitsubishi Tanabe, and several international entrants. The DPC system drives inpatient use, while the co-pay cap dynamics are less disadvantageous for adalimumab than for higher-cost biologics, given that its per-course cost is less likely to systematically push patients into the monthly cap reduction trigger.<\/p>\n\n\n\n

\n\n\n\n

Part II — Japan: Cracking the Co-Pay Paradox<\/strong><\/h2>\n\n\n\n

Market Size, Growth Trajectory, and Competitive Structure<\/strong><\/h3>\n\n\n\n

Japan’s biosimilar market, valued at approximately $502 million in 2024, is underperforming relative to its fundamental opportunity. The broader biologics market in Japan generates roughly $15 to $18 billion annually. With the government targeting 80% biosimilar usage volume for applicable molecules by 2029 — a target it is unlikely to hit on schedule — the theoretical addressable market is enormous.<\/p>\n\n\n\n

Growth forecasts range from a conservative 9.3% CAGR to an aggressive 22% depending on whether the government’s reimbursement interventions succeed in resolving the co-pay paradox described below. The 22% scenario requires a meaningful policy correction; the 9.3% scenario reflects trend continuation without structural change.<\/p>\n\n\n\n

Therapeutic concentration is high. Oncology — trastuzumab, bevacizumab, rituximab, cetuximab — and autoimmune disorders — infliximab, etanercept, adalimumab — account for more than 70% of biosimilar spend. The filgrastim (G-CSF) segment, a first-generation biosimilar category, remains a significant volume contributor in the inpatient oncology setting due to its DPC dynamics. Ophthalmology biosimilars represent the next significant growth category as ranibizumab and aflibercept approach their Japanese patent cliffs.<\/p>\n\n\n\n

The competitive structure is a mix of global originators running biosame strategies, foreign biosimilar specialists partnering with domestic distributors, and a limited number of Japanese manufacturers with in-house biologic manufacturing capability. The barriers to independent commercial launch for foreign entrants without a domestic partner are high, given the complexity of hospital contracting and the importance of established relationships with the PMDA and the Central Social Insurance Medical Council (Chuikyo), the body that sets reimbursement prices.<\/p>\n\n\n\n

\n\n\n\n

PMDA Pathway: Full Technical Breakdown<\/strong><\/h3>\n\n\n\n

Definition Scope and Reference Product Requirements<\/strong><\/h4>\n\n\n\n

The PMDA defines a biosimilar as a biological product that demonstrates comparability to an already-approved originator biological in Japan with respect to quality, safety, and efficacy. The agency’s guidelines, first issued in 2009 and updated with Q&A supplements through 2024, cover recombinant proteins expressed in microbial, yeast, insect, or mammalian cells, including mAbs, Fc-fusion proteins, enzymes, hormones, and cytokines. Cell therapy products, blood-derived products, and allergen extracts fall outside the standard biosimilar framework.<\/p>\n\n\n\n

The reference product must be an originator approved in Japan based on a full data dossier. Products approved in Japan on the basis of a foreign reference product (i.e., products imported and approved under a Japanese New Drug Application relying on overseas data) are not eligible as comparators under standard rules. This requirement creates a complexity: if a product was approved in the EU five years before it was approved in Japan, the EU product has been the reference for European biosimilar programs, but Japanese biosimilar applicants must use the Japan-approved version as their primary comparator, which may have different batch history, formulation minor variations, or manufacturing site history.<\/p>\n\n\n\n

Analytical Similarity: Orthogonal Methods and the PMDA’s Emphasis on Quality<\/strong><\/h4>\n\n\n\n

The PMDA places greater relative weight on the analytical similarity package than most other major regulators. This is consistent with Japan’s broader pharmaceutical culture, where quality assurance has historically been a primary professional and regulatory concern, and where the ‘totality of the evidence’ principle is interpreted to mean that outstanding analytical data can substantially reduce the clinical development burden.<\/p>\n\n\n\n

Required analytical methods include peptide mapping with LC-MS\/MS for primary sequence confirmation, intact mass analysis for gross molecular weight, N-glycan profiling by HPLC or CE-LIF with mass spectrometry confirmation, charge heterogeneity profiling by isoelectric focusing and cation exchange chromatography, size exclusion chromatography for aggregate quantification, subunit analysis under reducing and non-reducing conditions, and a panel of biological activity assays covering all known mechanisms of action. The PMDA expects method validation for all analytical procedures, with acceptance criteria justified in the context of reference product variability data.<\/p>\n\n\n\n

For clinical PK studies, the PMDA accepts data from non-Japanese subjects, provided the applicant submits a justified analysis of relevant ethnic pharmacogenomic factors. CYP450-mediated metabolism is not relevant for mAbs, but target receptor polymorphisms that affect drug-target binding kinetics can, in principle, create ethnic differences in PK. For most mAbs, the scientific justification is straightforward, and the PMDA’s 2023 guidance updates made the ethnic-factor waiver a more predictable part of the submission pathway.<\/p>\n\n\n\n

Post-Marketing Requirements: RMP and Safety Database Obligations<\/strong><\/h4>\n\n\n\n

The PMDA’s Risk Management Plan requirement for biosimilars is detailed and closely monitored. The RMP must specify safety concerns — identified risks, potential risks, and missing information — and define pharmacovigilance activities and risk minimization measures for each. For biosimilars, the PMDA specifically requires routine and enhanced pharmacovigilance systems capable of distinguishing adverse events attributable to the biosimilar from those attributable to the reference product, an important traceability requirement given that both products may be in concurrent use in Japan.<\/p>\n\n\n\n

Post-marketing studies evaluating long-term immunogenicity are a standard PMDA expectation. Anti-drug antibody (ADA) development is the primary immunogenicity concern for protein therapeutics, and the PMDA requires prospective detection, characterization (neutralizing vs. non-neutralizing), and clinical impact assessment of ADAs in the post-marketing setting. This data feeds into periodic benefit-risk evaluation reports submitted on a schedule determined by the initial RMP.<\/p>\n\n\n\n

\n\n\n\n

The Reimbursement Labyrinth: DPC, Co-Pay Caps, and Financial Incentives<\/strong><\/h3>\n\n\n\n

The Structural Architecture of Japanese Drug Reimbursement<\/strong><\/h4>\n\n\n\n

Japan operates a universal health insurance system where the government sets reimbursement prices for all approved drugs through a biennial revision process. The NHI drug price list (yakka) assigns a specific yen price to every approved drug. When a biosimilar is approved, it receives its own NHI price, typically set at 70% of the reference product’s price in the first pricing cycle, with further reductions in subsequent cycles if the product does not achieve market penetration targets.<\/p>\n\n\n\n

This pricing architecture creates a transparent and predictable revenue model: a biosimilar developer knows the maximum reimbursable price from the day of approval. The commercial uncertainty lies in the volume capture, which is where the co-pay paradox and DPC dynamics become decisive.<\/p>\n\n\n\n

The Co-Pay Cap Mechanism: The Paradox Explained Precisely<\/strong><\/h4>\n\n\n\n

The co-pay structure operates as follows. Patients under 70 years old generally pay 30% of drug costs up to a monthly maximum, which varies by income tier. Once a patient’s total monthly healthcare out-of-pocket expenditure (across all services and drugs) reaches this maximum, the government absorbs all additional costs. After this maximum has been reached three times within a 12-month window, the maximum is reduced — permanently lowered for that patient during that coverage year.<\/p>\n\n\n\n

For patients on high-cost biologic therapies, the monthly drug cost alone is often sufficient to trigger the cap. An infliximab infusion at the originator’s NHI price might generate a monthly co-pay of 80,000 to 100,000 yen for a standard 5 mg\/kg dose before the cap kicks in. Once the patient reliably hits the cap, their marginal monthly cost for every subsequent infusion is zero. The biosimilar, priced at 70% of the originator, reduces the monthly drug cost to a level that may no longer trigger the cap as quickly or as reliably — meaning the patient’s out-of-pocket cost paradoxically increases when they switch to the cheaper product.<\/p>\n\n\n\n

This is not a theoretical edge case. McKinsey’s analysis of the infliximab biosimilar launch in Japan identified this mechanism as the principal factor explaining why infliximab biosimilar penetration in Japan was significantly below that seen in Germany, the Netherlands, and the Nordic countries, where flat co-pay structures or reference pricing systems create direct patient cost incentives to use biosimilars.<\/p>\n\n\n\n

The paradox does not apply uniformly. For biologics with monthly drug costs that fall below the cap threshold, such as etanercept at standard doses, the co-pay is a fixed percentage with no cap triggering, and biosimilar price reductions translate directly into patient savings. This explains why etanercept biosimilars achieved much higher penetration rates in Japan than infliximab biosimilars in comparable time periods post-launch.<\/p>\n\n\n\n

DPC: The Inpatient Incentive That Works<\/strong><\/h4>\n\n\n\n

The Diagnostic Procedure Combination (DPC) system covers approximately 55% of all general hospital beds in Japan, applying a fixed per-diem payment rate to each hospitalized patient based on their diagnosis code and associated treatment category. The hospital receives the same payment regardless of whether it administers the originator biologic or the biosimilar. Every yen saved on drug acquisition translates directly to the hospital’s operating margin.<\/p>\n\n\n\n

This mechanism drove filgrastim biosimilar penetration to over 70% in the inpatient oncology setting within a few years of approval, and is the primary force accelerating trastuzumab and bevacizumab biosimilar uptake in hospitals with high DPC coverage. The commercial implication for biosimilar developers is clear: market access strategy in Japan must be segmented by care setting. The inpatient oncology and rheumatology teams at major academic medical centers and DPC-covered hospitals are the primary commercial targets, because the financial incentive to switch is structural, durable, and independent of physician education about biosimilar science.<\/p>\n\n\n\n

The 1,500-Yen Prescriber Incentive and Its Documented Effectiveness<\/strong><\/h4>\n\n\n\n

Japan’s Ministry of Health, Labour and Welfare (MHLW) has experimented with direct financial incentives to accelerate biosimilar uptake. A premium of approximately 1,500 yen per biosimilar prescription, available to prescribing physicians for a defined initial period, generated a measurable and statistically significant increase in trastuzumab biosimilar prescription rates in a 2024 study published in a peer-reviewed pharmacoeconomics journal. The effect was concentrated in outpatient settings where the DPC incentive does not apply and where the co-pay paradox is most acute.<\/p>\n\n\n\n

The mechanism is analogous to the pay-for-performance bonuses used in the UK’s NHS Quality and Outcomes Framework and in US Medicare’s Merit-Based Incentive Payment System (MIPS), though at a much smaller absolute scale. The documented effectiveness of even modest financial nudges suggests that expanding the incentive program — broadening the molecule list, increasing the premium amount, or extending the eligibility period — could meaningfully accelerate Japan’s progress toward its biosimilar penetration targets.<\/p>\n\n\n\n

\n\n\n\n

IP Valuation: Trastuzumab, Bevacizumab, and the Evergreening Playbook in Japan<\/strong><\/h3>\n\n\n\n

The Japan-Specific Patent Landscape<\/strong><\/h4>\n\n\n\n

Japan’s patent term is 20 years from filing, with a patent term extension (PTE) available for up to five additional years to compensate for the time lost to regulatory review. PTE applications for biologics are common and are evaluated by the Japan Patent Office (JPO) using the same first-marketing approval date reference used in the US and EU systems. For a biologic first approved in Japan in 2002 with a 2019 patent expiration, a five-year PTE could extend protection to 2024, significantly affecting the biosimilar market entry timeline.<\/p>\n\n\n\n

The critical strategic insight for biosimilar developers is that the Japanese patent register is a distinct landscape from the US or European registers. A patent that has expired in the US may still be active in Japan if it was filed later, has a different prosecution history, or received a PTE based on the Japanese approval date. Developers who assume that the European biosimilar launch timeline applies directly to Japan make a systematic error with real cost consequences.<\/p>\n\n\n\n

Evergreening Tactics and the Japan-Specific Counter-Strategies<\/strong><\/h4>\n\n\n\n

Originator companies use several standard evergreening tactics in Japan:<\/p>\n\n\n\n

Formulation patents on pH, concentration, buffer system, and excipient composition are filed routinely and can extend effective market exclusivity by three to seven years beyond composition-of-matter patent expiry. The Japanese courts have been willing to enforce formulation patents with relatively narrow scope — meaning a biosimilar developer can often design around a formulation patent by adopting a different buffer system that achieves the same stability goals, provided they can demonstrate equivalent quality attributes.<\/p>\n\n\n\n

Process patents covering specific chromatography resins, viral inactivation parameters, or filtration configurations are increasingly common. These are difficult to detect through public patent records alone because the manufacturing process is not disclosed in regulatory submissions or published literature. Biosimilar developers must identify these patents through patent landscaping and then design processes that achieve equivalent purity profiles through different means.<\/p>\n\n\n\n

Device patents on auto-injectors, safety syringes, and combination products represent the newest and most commercially impactful form of evergreening. The commercial success of the NIPRO\/Owen Mumford UniSafe syringe biosimilar launch in Japan illustrates that device differentiation cuts both ways: originators use it to defend share by migrating patients to device-locked branded combinations, but biosimilar developers who invest in superior device engineering can use device quality as a positive commercial differentiator rather than simply trying to replicate the originator’s device.<\/p>\n\n\n\n

\n\n\n\n

Competitive Dynamics: ‘Biosames,’ Device Differentiation, and Key Players<\/strong><\/h3>\n\n\n\n

The Biosame Phenomenon: Originator Self-Cannibalization as Defense<\/strong><\/h4>\n\n\n\n

The ‘biosame’ strategy represents one of the most sophisticated competitive tactics in the Japanese market. When Kyowa Kirin launched a biosame version of its own Nesp (darbepoetin alfa) in 2019 at a price point equivalent to incoming biosimilar competition, it used three simultaneous advantages that no independent biosimilar entrant could match: an already-established physician relationship with the product, an existing manufacturing line with known regulatory history, and brand recognition built over years of clinical use.<\/p>\n\n\n\n

The biosame strategy effectively collapses the price gap that would otherwise accrue to biosimilar entrants while retaining the originator’s commercial infrastructure advantage. From a market structure perspective, it is equivalent to a fast follower launching a ‘premium generic’ — product identical in molecule, price-competitive with biosimilars, but carrying the brand equity of the originator.<\/p>\n\n\n\n

Biosame strategies are most viable for originators with substantial domestic manufacturing capability in Japan. Companies that rely entirely on overseas production may find the Japan-specific NHI pricing and post-marketing obligations for a biosame too costly relative to the benefit of share defense. The strategy is therefore particularly relevant for Japanese domestic originators like Kyowa Kirin, Chugai, and Takeda, rather than for US or European multinationals manufacturing in Ireland or Singapore.<\/p>\n\n\n\n

Key Commercial Players<\/strong><\/h4>\n\n\n\n

The Japan biosimilar market has a distinct competitive map. Global biosimilar specialists including Sandoz (Novartis), Pfizer, and Amgen compete with specialized Japanese distributors who hold the commercial rights for Korean biosimilars. Celltrion’s products reach the Japanese market through licensing and distribution arrangements rather than direct commercialization. Samsung Bioepis products have entered through partnerships with Organon and local distributors.<\/p>\n\n\n\n

Domestic Japanese companies active in biosimilar development include Daiichi Sankyo, which has developed its own adalimumab biosimilar, and Kyowa Kirin, which manages its biosame program independently. The Japanese generics-to-biosimilar conversion companies — Sawai, Towa, and Nichi-Iko — have not developed significant biosimilar positions, as the manufacturing complexity is beyond their current capabilities.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways — Japan<\/strong><\/h3>\n\n\n\n

Japan’s biosimilar market offers the highest revenue per product of the three markets covered here, but the path to realizing that revenue requires resolving the co-pay paradox through careful pricing strategy and a segmented market access approach. The DPC inpatient system creates a durable structural incentive that should be the primary commercial focus at launch, with outpatient penetration following as physician education and government incentives build confidence and change prescribing habits over time. Formulation, device, and process patent evergreening is active and creates a meaningfully different launch timeline in Japan versus Europe or the US for several key molecules. Regulatory acceptance of foreign clinical data reduces the incremental development cost for Japan market entry, making a Japan market entry viable as an extension of a global program rather than a standalone investment.<\/p>\n\n\n\n

Investment Strategy — Japan<\/strong><\/h3>\n\n\n\n

Portfolio managers evaluating biosimilar-focused companies with Japan exposure should weight several factors specifically. Revenue recognition timing is affected by the NHI biennial price revision cycle — a product launched in year one of a cycle receives full pricing for two years before its first downward revision, while a product launched in year two faces an early price cut. Market penetration rates for the inpatient segment are more predictable and faster than outpatient, so near-term revenue forecasts for any new Japanese biosimilar launch should be modeled with higher confidence in the DPC segment than in the outpatient rheumatology or dermatology segment. Companies with strong hospital relationships and existing DPC-covered hospital contracting infrastructure have a durable commercial advantage that is difficult to replicate on a short timeline. The device differentiation opportunity is underappreciated: the NIPRO\/UniSafe case demonstrates that a superior delivery device can produce disproportionate market share gains in a market that typically selects on price alone.<\/p>\n\n\n\n

\n\n\n\n

Part III — South Korea: How a Government Builds a Global Powerhouse<\/strong><\/h2>\n\n\n\n

Market Size, CAGR, and Export Architecture<\/strong><\/h3>\n\n\n\n

South Korea’s biosimilar market reached approximately $531 million in 2023 and is projected to exceed $1.6 billion by 2027 at a CAGR of 22.5%. The domestic market, while significant, is not the strategic focus of the Korean national biosimilar program. The real objective is export revenue: Korean companies have built their entire commercial infrastructure around capturing share in the US, European, and Japanese markets, with the domestic market serving primarily as a regulatory credentialing platform.<\/p>\n\n\n\n

The South Korean biopharma market as a whole is approximately $22 billion, making it the 13th largest pharmaceutical market globally. As of 2024, companies headquartered in South Korea had developed the second-highest number of FDA-approved biosimilars of any country, behind the United States itself. By early 2026, that position was reinforced by ongoing FDA approvals from Celltrion’s and Samsung Bioepis’s expanding pipelines.<\/p>\n\n\n\n

The geographic concentration of biomanufacturing capacity in Songdo, Incheon — a purpose-built biotechnology city — is strategically significant. Songdo now has the single largest concentration of biopharmaceutical manufacturing capacity at a single location in the world, combining Samsung Biologics’ four production facilities, Celltrion’s dedicated manufacturing complex, and contract development manufacturing (CDMO) operations that serve both domestic companies and global clients. This geographic concentration enables shared infrastructure, labor pool depth, and supply chain efficiency that generates durable cost advantages.<\/p>\n\n\n\n

\n\n\n\n

The Third Five-Year Plan: Targets, Funding, and Industrial Logic<\/strong><\/h3>\n\n\n\n

National Target Architecture: 2023-2027<\/strong><\/h4>\n\n\n\n

The South Korean government’s Third Five-Year Comprehensive Plan for the Development and Support of the Bio-Pharmaceutical Industry (2023-2027), jointly managed by the Ministry of Health and Welfare (MOHW), the Ministry of Science and ICT (MSIT), and the Ministry of Trade, Industry and Energy (MOTIE), sets the following national targets for 2027:<\/p>\n\n\n\n

Development of two new blockbuster drug products each generating more than $700 million in annual revenue. Elevation of at least three Korean domestic companies into the global top-50 pharmaceutical companies by revenue. Growth of pharmaceutical export revenue to $16 billion, representing a doubling of the pre-Plan baseline. Achievement of third-place global ranking in clinical trial site volume, measured by the number of active investigational new drug studies conducted in Korean facilities.<\/p>\n\n\n\n

These are not advisory targets. They are backed by specific funding mechanisms, regulatory commitments, and infrastructure investments that create concrete institutional accountability for outcomes.<\/p>\n\n\n\n

The K-Bio Vaccine Fund and Capital Deployment<\/strong><\/h4>\n\n\n\n

The Plan allocates a KRW 1 trillion (approximately $720 million at 2024 exchange rates) K-Bio Vaccine Fund specifically for R&D and commercialization of vaccines and biologics, including biosimilars. A second, larger mega-fund focused on late-stage clinical development and global market entry was in development as of early 2026. These funds operate as government-backed investment vehicles, co-investing with private capital rather than providing grants, which aligns government and private investor risk more closely than traditional subsidy programs.<\/p>\n\n\n\n

Public-private co-investment in AI-driven drug discovery, digital manufacturing twins for bioprocess optimization, and real-world evidence platforms were explicitly funded in the Plan. The AI component is not decorative: Samsung Biologics has deployed machine learning models for fed-batch optimization that have improved titer consistency and glycoform reproducibility at commercial scale, a direct competitive advantage in the CDMO business where process reliability is the primary selection criterion for clients.<\/p>\n\n\n\n

Bio-Cluster Infrastructure and Regulatory Streamlining<\/strong><\/h4>\n\n\n\n

The Songdo International Business District serves as the anchor bio-cluster, with satellite clusters established in Osong (North Chungcheong Province), Daejeon (the national research and development hub), and Pangyo (adjacent to Seoul). Each cluster combines wet laboratory infrastructure, GMP manufacturing space, regulatory affairs support from co-located government agencies, and access to academic institution partnerships. Companies establishing operations within designated cluster boundaries receive corporate tax reductions, accelerated equipment depreciation, and priority access to government-sponsored clinical trial networks.<\/p>\n\n\n\n

Regulatory streamlining is operationally concrete. The MFDS announced a dedicated fast-track review program for biosimilars beginning in 2026, targeting reduction of total review time from the current median of approximately 18 months to under 12 months for applications meeting pre-specified completeness criteria. This acceleration is achievable in part because Korean biosimilar developers filing with the MFDS typically also hold EMA or FDA approval, providing the MFDS with a high-quality precedent data package that reduces the MFDS’s independent analytical burden.<\/p>\n\n\n\n

\n\n\n\n

MFDS Pathway: Harmonization as Competitive Strategy<\/strong><\/h3>\n\n\n\n

The Strategic Design of Korean Regulatory Alignment<\/strong><\/h4>\n\n\n\n

When the MFDS issued its first biosimilar guidelines in 2009, harmonizing with the WHO, EMA, and PMDA frameworks was not merely a scientific choice — it was an export strategy. A Korean biosimilar meeting MFDS requirements was designed, from inception, to also meet EMA and (with incremental additional data) FDA requirements. This integration of regulatory compliance with commercial market access is the operational core of the Korean biosimilar model.<\/p>\n\n\n\n

The reference product framework in Korea requires the comparator to be an originator approved in Korea via a full data dossier. Foreign-sourced reference products — for example, using the EU-approved originator as the primary comparator in a development program — are acceptable with a bridging study demonstrating analytical equivalence between the EU-sourced and Korea-approved reference. This flexibility is commercially important: Korean companies running global development programs can use the same reference product lots across their entire regulatory filing strategy, reducing the total volume of reference material needed and streamlining the analytical comparability database.<\/p>\n\n\n\n

Extrapolation is permitted by the MFDS with the same scientific standards as the EMA: mechanism-of-action consistency across extrapolated indications, no population-specific safety concerns, and adequate overall characterization of the biosimilar in the studied indication. The MFDS has a track record of granting broad extrapolation for well-characterized mAbs, supporting the commercial viability of single-indication clinical programs.<\/p>\n\n\n\n

\n\n\n\n

IP Valuation: Celltrion’s Remsima Portfolio and the Paragraph IV Equivalent<\/strong><\/h3>\n\n\n\n

Remsima (Infliximab): A First-Mover IP Asset Worth Analyzing Precisely<\/strong><\/h4>\n\n\n\n

Celltrion’s Remsima was the world’s first approved monoclonal antibody biosimilar, receiving Korean approval in 2012 and EMA approval in 2013. The IP value of Remsima is no longer in the product itself — infliximab’s global market has been heavily penetrated by biosimilar competition — but in what Remsima demonstrated: that a Korean company could develop, manufacture, and gain regulatory approval for a complex mAb biosimilar at world-class quality standards, then commercialize it globally.<\/p>\n\n\n\n

The ‘first approved mAb biosimilar’ status created durable brand equity that translates into physician trust and formulary positioning in markets where biosimilar adoption is still building. Remsima has also been the platform for Remsima SC, Celltrion’s subcutaneous reformulation of infliximab. This product exemplifies the biobetter strategy: by developing a subcutaneous formulation co-administered with hyaluronidase, Celltrion created a genuinely improved product with new IP, different MFDS and EMA approval dates, and a distinct commercial position that is difficult for pure biosimilar competitors to replicate without independent subcutaneous formulation development programs.<\/p>\n\n\n\n

For IP valuation, Remsima SC’s value lies in the new patent estate covering the subcutaneous formulation and the proprietary co-administration technology. Unlike a standard biosimilar, which can only compete on price and quality, Remsima SC competes on delivery convenience and a distinct clinical positioning, making it more defensible against subsequent competition and capable of maintaining a premium price relative to the IV formulation.<\/p>\n\n\n\n

The Korean ‘Paragraph IV Equivalent’ Dynamic<\/strong><\/h4>\n\n\n\n

Korea’s pharmaceutical patent challenge system, while structured differently from the US Hatch-Waxman Paragraph IV framework, produces analogous commercial dynamics. When a Korean biosimilar developer files with the MFDS and there are active Korean patents covering the reference product, the originator company receives notification, triggering a period for patent dispute resolution. The commercial implications — first-filer advantages, at-risk launch decisions, settlement agreements that may include market entry date provisions — parallel the US experience, though the specific legal procedures differ.<\/p>\n\n\n\n

For international developers, understanding the specific Korean patent challenge precedents for infliximab, trastuzumab, and adalimumab is essential before filing the MFDS application for any molecule in these classes. The Korean Intellectual Property Office (KIPO) maintains an accessible patent register, and MFDS notification procedures are documented in the agency’s pharmaceutical affairs regulations. These records, combined with litigation databases maintained by Korean IP law firms, constitute the primary intelligence source for Korean launch timing analysis.<\/p>\n\n\n\n

\n\n\n\n

Celltrion: Pioneer Strategy, US Manufacturing, and 2030 Pipeline<\/strong><\/h3>\n\n\n\n

The 22-Product Portfolio Commitment<\/strong><\/h4>\n\n\n\n

Celltrion’s stated goal of commercializing a portfolio of 22 biosimilar products by 2030 is not aspirational window dressing. As of early 2026, the company had approximately 11 biosimilars approved across major markets, with a further seven to eleven products in various stages of late clinical development or regulatory review. The 2030 portfolio includes products in ophthalmology (ranibizumab biosimilar), oncology immunotherapy (pembrolizumab biosimilar, where Keytruda’s key patents are expected to expire around 2028 in most major markets), and dermatology (ustekinumab biosimilar, competing against Johnson & Johnson’s Stelara).<\/p>\n\n\n\n

Each of these pipeline additions represents a distinct IP landscape challenge, a separate clinical development program, and a separate market access investment. The total investment required to execute the 22-product strategy across development, manufacturing, and commercialization exceeds $5 billion over the period, suggesting that Celltrion’s capital allocation strategy — including the decision to maintain its own direct commercialization infrastructure in the EU and US rather than relying on partners — requires continued access to debt and equity capital at favorable terms. Any investor modeling Celltrion should stress-test the capital structure against scenarios where launch timing delays or pricing pressure in one or more key markets reduce expected cash flow.<\/p>\n\n\n\n

US Manufacturing Acquisition: Tariff Mitigation and Strategic Signaling<\/strong><\/h4>\n\n\n\n

Celltrion’s announced acquisition of a large-scale US biologics manufacturing facility in 2025, detailed in a letter to shareholders, is a multi-objective strategic move. The stated primary objective is tariff mitigation. The possibility of US pharmaceutical import tariffs — discussed seriously in the US executive branch and Congress through 2024 and 2025 — creates specific commercial risk for a company with all existing manufacturing in South Korea and Ireland. A US-sited drug substance manufacturing facility converts the risk profile from a currency and trade policy exposure to a domestic production story with ‘Made in USA’ marketing value.<\/p>\n\n\n\n

The secondary objective is supply chain diversification. A single-country manufacturing model, even with Korea’s world-class facilities, concentrates geopolitical and natural disaster risk. The US facility provides a second manufacturing node that can backstop Korean production during disruptions, supporting FDA and EMA supply commitments under Product Shortage Prevention frameworks.<\/p>\n\n\n\n

The tertiary objective is regulatory relationship building. A company manufacturing in the US employs a US workforce, pays US corporate taxes, and has standing to engage directly with FDA manufacturing quality and biosimilar policy teams in a way that foreign manufacturers do not. This matters for the ongoing relationship with the FDA on manufacturing supplements, post-approval changes, and the agency’s evolving interchangeability designation framework.<\/p>\n\n\n\n

Direct EU and US Commercialization: The P&L Implications<\/strong><\/h4>\n\n\n\n

Celltrion’s decision to build direct sales and marketing infrastructure in Europe (beginning 2019) and the US (beginning 2023) rather than continuing to rely on commercial partners produces significantly higher gross margins per unit sold at the cost of higher fixed operating expenses. The margin benefit of eliminating a commercial partner’s 25-35% take on net sales is substantial over the long term, but the fixed cost structure creates operating leverage risk: if biosimilar pricing deteriorates faster than expected due to competitive dynamics, the direct commercial model’s fixed costs magnify the downside versus a partnership model where cost of sales is variable.<\/p>\n\n\n\n

\n\n\n\n

Samsung Bioepis: Partnership Architecture and the Spinoff Rationale<\/strong><\/h3>\n\n\n\n

The Partnership-First Commercial Model<\/strong><\/h4>\n\n\n\n

Samsung Bioepis has chosen a fundamentally different commercial architecture than Celltrion. The company focuses its resources on R&D, process development, and manufacturing, delegating commercialization to global partners with existing market access infrastructure. Biogen has been the primary US commercialization partner for Samsung Bioepis products, including its adalimumab biosimilar (Hadlima), its etanercept biosimilar (Benepali), and its ranibizumab biosimilar (Byooviz). Organon acquired commercialization rights to Samsung Bioepis’s US and European biosimilar portfolio from Merck in 2021, taking on several additional products.<\/p>\n\n\n\n

The partnership model’s advantage is capital efficiency. Samsung Bioepis does not maintain a global salesforce or country-by-country market access team, which allows it to deploy its capital more intensively toward pipeline expansion and manufacturing excellence. The disadvantage is revenue share dilution and strategic dependence on partners whose priorities and market execution capabilities may not align perfectly with Samsung Bioepis’s own commercial goals. Biogen’s 2025 decision to exit the ophthalmology biosimilar space — transferring Samsung Bioepis’s ranibizumab commercialization rights to Harrow — illustrates this risk: Samsung Bioepis had no control over Biogen’s strategic exit and had to manage the transition to a new partner without disrupting supply and market access in the middle of a commercial launch.<\/p>\n\n\n\n

The Samsung Biologics Spinoff: Strategic Logic and IP Separation<\/strong><\/h4>\n\n\n\n

Samsung Biologics’ announced intention to spin off Samsung Bioepis into an independent publicly traded entity addresses a structural conflict of interest that has increasingly complicated the CDMO business. Samsung Biologics competes directly with Lonza, WuXi Biologics, Boehringer Ingelheim, and Catalent for CDMO manufacturing contracts. Potential CDMO clients who are originator biologic companies face a conflict in contracting manufacturing to Samsung Biologics while Samsung Bioepis develops biosimilars targeting those very same originators’ products.<\/p>\n\n\n\n

The spinoff separates the two businesses’ IP estates, competitive positions, and governance structures. Samsung Biologics post-spinoff becomes a pure CDMO without any biosimilar development assets, eliminating the conflict of interest for originator CDMO clients. Samsung Bioepis post-spinoff becomes a fully independent biosimilar and novel drug development company with its own capital markets strategy, a cleaner IP ownership structure, and the ability to make acquisition and partnership decisions without Samsung Biologics board-level conflict-of-interest considerations.<\/p>\n\n\n\n

For analysts, the post-spinoff Samsung Bioepis is a more comparable entity to Celltrion — a pure-play biosimilar developer with a specific pipeline, known cost structure, and defined commercial strategy. Valuation multiples applicable to biosimilar-focused companies apply cleanly, rather than the mixed CDMO\/biosimilar conglomerate discount that applied to the pre-spinoff structure.<\/p>\n\n\n\n

\n\n\n\n

Technology Roadmap: Korean Biomanufacturing Scale and CHO Cell Advancement<\/strong><\/h3>\n\n\n\n

Samsung Biologics’ Four-Facility Capacity Stack<\/strong><\/h4>\n\n\n\n

Samsung Biologics has built commercial-scale biomanufacturing capacity in four sequential tranches in Songdo. The first three facilities, operational between 2011 and 2020, provide a combined installed capacity of approximately 180,000 liters of fed-batch bioreactor volume, making Samsung Biologics the largest single-site CDMO globally by volume. The fourth facility, completed in 2023, added an incremental 240,000 liters and introduced both additional fed-batch trains and an intensified perfusion manufacturing suite designed to serve the next generation of biologic products, including cell and gene therapies, which require different process modalities than conventional mAbs.<\/p>\n\n\n\n

The fifth facility, announced in 2023 and under construction as of early 2026, targets an additional 180,000 liters, bringing total installed Songdo capacity above 600,000 liters by 2025-2026. At current commercial mAb titers of 5 to 8 grams per liter over a 14-day cycle, this capacity can theoretically produce 300 to 400 metric tons of mAb drug substance per year, dwarfing any individual originator’s in-house biomanufacturing footprint.<\/p>\n\n\n\n

Process Intensification and the Next Generation of Efficiency<\/strong><\/h4>\n\n\n\n

Korean CDMO and biosimilar companies are actively investing in process intensification technologies that reduce the cost of goods for biosimilar production. Continuous manufacturing approaches that replace batch upstream and downstream processing with continuous bioprocessing trains — cell retention devices, continuous capture chromatography, inline virus inactivation — can reduce facility footprint by 40-60%, cut manufacturing cycle time from weeks to days, and improve batch-to-batch consistency by minimizing process variable accumulation over long culture durations.<\/p>\n\n\n\n

Samsung Biologics and Celltrion have both published process development results indicating pilot-scale implementation of continuous bioprocessing for selected mAb products. Full commercial-scale validation of continuous manufacturing for a biosimilar product is expected by 2027, at which point the regulatory pathway for continuous manufacturing supplements will be better defined by the FDA and EMA. This investment has direct IP implications: continuous manufacturing processes generate new patentable process innovations distinct from the batch processes of the reference product, potentially providing additional IP protection for the Korean manufacturers’ biosimilar products.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways — South Korea<\/strong><\/h3>\n\n\n\n

South Korea’s biosimilar success is structural, not accidental. State capital, regulatory alignment with export markets, and purpose-built manufacturing infrastructure created an ecosystem where Celltrion and Samsung Bioepis could reach global scale faster than any private-sector-only model would have permitted. For non-Korean companies, competing head-on in mainstream mAb categories against these national champions in their home market is a losing strategy. The viable alternatives are licensing or distribution partnerships that access the Korean manufacturing cost base, niche therapeutic area focus in categories where Korean pipeline coverage is thin, or biobetter\/next-generation product strategies that compete on differentiation rather than price.<\/p>\n\n\n\n

Investment Strategy — South Korea<\/strong><\/h3>\n\n\n\n

Institutional investors evaluating Korean biosimilar companies should build their models around three distinct revenue streams: domestic Korean market sales (lower margins, driven by government price controls), export royalties and milestone payments from commercial partnerships in the US and EU (high margin, lumpy timing), and direct commercialization revenue from Celltrion’s own EU and US salesforce (high top-line, high fixed cost structure with operating leverage). The Celltrion US manufacturing acquisition changes the tariff risk profile materially. Analysts who modeled 15-20% tariff sensitivity on Korean-manufactured product shipped to the US should revise those models to reflect the partial mitigation of domestic US production. Samsung Bioepis post-spinoff warrants re-rating as a pure-play biosimilar compounder: revenue visibility is higher, margin structure is cleaner, and the CDMO conflict-of-interest discount disappears.<\/p>\n\n\n\n

\n\n\n\n

Part IV — Malaysia: The Procurement Bottleneck and the NPRA’s Precision Framework<\/strong><\/h2>\n\n\n\n

Market Size and the 800-Day Drug Lag<\/strong><\/h3>\n\n\n\n

Malaysia’s combined generic and biosimilar pharmaceutical market was valued at approximately $898.7 million in 2022 and is forecast to reach $1.24 billion by 2030, representing a CAGR of roughly 4%. The biosimilar component is a subset of this figure and is not separately disclosed in government statistics with granularity, but industry estimates place biosimilar-specific spend at $60 to $80 million annually, a fraction of Japan’s or South Korea’s scale.<\/p>\n\n\n\n

The structural drag on market development is the 800-day median approval lag documented in a 2023 retrospective study published in the Journal of Applied Pharmaceutical Science. This metric measures the median time between a biosimilar’s first approval in a major reference jurisdiction (typically the EU) and its subsequent NPRA approval. An 800-day lag means that by the time a biosimilar reaches the Malaysian market, it is already three to five years into its commercial life in Europe. The competitive dynamics, clinical adoption data, and physician confidence built in the EU market are valuable but do not automatically transfer to Malaysia’s procurement and prescribing environment, requiring a largely independent market access investment.<\/p>\n\n\n\n

The drivers of the lag are multiple. Applicant submission timing is often the primary factor — companies prioritize major market submissions and file Malaysia as a secondary or tertiary market. NPRA review timelines, while not globally the slowest, are affected by resource constraints and queue management. Reference product bridging requirements add analytical work for products that were not originally developed with Malaysia as a primary market. The 2023 NPRA guideline update addressed some procedural clarity issues, and the NPRA has publicly committed to accelerated review timelines for products with existing EMA or FDA approval, but the 800-day lag figure reflects years of accumulated backlog that will take time to resolve.<\/p>\n\n\n\n

\n\n\n\n

NPRA Pathway: December 2023 Updates and Interchangeability Rules<\/strong><\/h3>\n\n\n\n

Second-Edition Guidance Document: Key Technical Changes<\/strong><\/h4>\n\n\n\n

The NPRA’s December 2023 second edition of its Guidance Document and Guidelines for Registration of Biosimilars in Malaysia incorporated updates from the WHO’s 2022 biosimilar guideline revision. The key technical changes include expanded guidance on analytical similarity assessment, specifically the application of quality range approaches for setting specification limits that reflect reference product variability; updated pharmacovigilance requirements aligned with the ICH E2E guideline structure; and a new section on biosimilar naming conventions for traceability, requiring non-proprietary name plus suffix identification on all prescriptions and dispensing records.<\/p>\n\n\n\n

The interchangeability and substitution clarifications in the second edition formalized a policy that had been operationally in place but previously under-documented. The NPRA’s position is that once a biosimilar is registered, a prescriber may choose it or the reference product with confidence that both will produce the same therapeutic effect — clinical interchangeability for prescribing choice. Automatic pharmacy-level substitution is explicitly and unambiguously prohibited. All biologics, including biosimilars, must be prescribed by brand name, not by international non-proprietary name (INN) alone. This brand-name prescribing requirement is the enforcement mechanism for traceability: it ensures that if an adverse event occurs, the specific product and batch number can be identified in the pharmacovigilance database.<\/p>\n\n\n\n

Reference Product and Bridging Data Requirements<\/strong><\/h4>\n\n\n\n

The NPRA requires the comparator to be an innovator biologic registered in Malaysia on the basis of a full data dossier. This is a meaningful constraint. Not all reference products registered in Malaysia were submitted with a full dossier — some older products received approval under different regulatory frameworks. In those cases, the biosimilar applicant must conduct additional analytical characterization work to establish that the Malaysia-registered reference product is itself comparable to the well-characterized version used in the primary biosimilar development program.<\/p>\n\n\n\n

Foreign clinical data from EU or US biosimilar programs is acceptable provided the applicant includes a justification that Malaysian patient population pharmacokinetics are not expected to differ materially from the study population, and that the reference product used in the foreign study is analytically equivalent to the Malaysia-registered comparator. This double-bridging requirement — foreign program to Malaysian reference product, and foreign clinical population to Malaysian patient population — adds analytical and regulatory work that requires local regulatory expertise to execute efficiently.<\/p>\n\n\n\n

\n\n\n\n

The Procurement Puzzle: Tenders, Price Paradoxes, and Policy Contradictions<\/strong><\/h3>\n\n\n\n

The Three-Channel Public Procurement Architecture<\/strong><\/h4>\n\n\n\n

Malaysia’s Ministry of Health procures pharmaceuticals through three channels. The first is the APPL (Approved Pharmacy Products List), a direct procurement contract mechanism for a defined list of products, historically managed through a government-linked company concession structure. The second is centralized national tender management for high-volume, high-spend products. The third is direct hospital or clinic purchase for lower-value items below specified threshold procurement values.<\/p>\n\n\n\n

For biosimilars, the national tender is the primary access route. Tender cycles for major biologic categories occur every two to three years, with contract durations of one to two years. Winning a national tender provides access to the entire public sector network, which is the dominant channel for expensive biologic therapies given that most patients in Malaysia are treated in government facilities where drugs are provided free or at nominal cost.<\/p>\n\n\n\n

The Price Paradox: Policy Contradiction in Public View<\/strong><\/h4>\n\n\n\n

Reports from Malaysian industry associations and academic healthcare economists, published through 2024 and 2025, document a specific pattern: the MOH’s tender evaluation process has awarded contracts to locally manufactured generics and biosimilars at prices substantially above those offered by imported alternatives. The reported price premium range is 100 to 200% above the imported competitor price for the same molecule.<\/p>\n\n\n\n

The mechanism behind this outcome is the “Local Partner Advantage” (LPA) policy embedded in public procurement regulations, which gives preference and scoring advantages to products manufactured in Malaysia or supplied by Malaysian-registered companies under defined local content thresholds. When the LPA scoring weight is high enough, a locally produced product at double the price of an import can still achieve a higher total tender evaluation score.<\/p>\n\n\n\n

This creates a direct policy contradiction. The government’s official position, expressed in the MOH Position Statements on the Use of Biosimilars and in public health policy documents, states that biosimilars are endorsed as cost-effective tools to expand patient access. The procurement mechanism simultaneously generates above-market drug costs in the public sector, partially offsetting the cost savings that were the justification for adopting biosimilars in the first place.<\/p>\n\n\n\n

For foreign biosimilar developers, the LPA policy means that a competitive clinical and quality dossier is insufficient for tender success. The commercial strategy must include either a manufacturing presence in Malaysia, a partnership with a Malaysian-registered company with local content qualification, or a pricing strategy aggressive enough to overcome the LPA scoring premium of a local competitor.<\/p>\n\n\n\n

Transparency and Speed Challenges<\/strong><\/h4>\n\n\n\n

Independent of the LPA issue, Malaysia’s pharmaceutical tender process has documented operational problems. End-to-end tender duration from publication to contract award averages six to nine months, with some tenders taking longer due to evaluation appeals or procedural challenges. Historically, competing bid values were published post-award, providing market transparency; more recent reports from industry sources indicate that this transparency has diminished, making it harder for companies to assess whether their bids were competitively priced or whether evaluation criteria were applied consistently.<\/p>\n\n\n\n

Supply gap periods — the interval between the end of one tender contract and the start of the next, during which hospitals revert to spot purchases or experience shortages — are a documented problem for several biologic categories. These gaps create patient access interruptions and undermine the prescribing confidence that biosimilar market development depends on.<\/p>\n\n\n\n

\n\n\n\n

IP Valuation: What Biologics Approvals in Malaysia Are Actually Worth<\/strong><\/h3>\n\n\n\n

A Market Access Value Framework for Southeast Asia Entry<\/strong><\/h4>\n\n\n\n

Valuing an NPRA approval for a biosimilar requires a different framework than valuing an EMA or FDA approval. The absolute revenue opportunity — $60 to $80 million total addressable biosimilar market in Malaysia — is small relative to the development and regulatory submission costs. The strategic value of a Malaysian approval is therefore not primarily in Malaysia-specific revenue; it is in the following:<\/p>\n\n\n\n

Regional platform credibility: NPRA approval signals regulatory rigor sufficient to satisfy neighboring ASEAN markets, including Thailand (FDA Thailand), Vietnam (DAV), Indonesia (BPOM), and the Philippines (FDA Philippines), each of which applies its own framework but often treats NPRA approval as a favorable precedent.<\/p>\n\n\n\n

Investor signaling for Southeast Asia market development: for companies whose investment thesis includes building an ASEAN biosimilar presence, Malaysian approval is a credible proof point that the regulatory and commercial groundwork for regional expansion is in place.<\/p>\n\n\n\n

Government tender leverage: NPRA approval is a necessary but not sufficient condition for public procurement. Companies with NPRA approval and a local distribution or manufacturing partner are in a materially better position to win MOH tenders than companies with approval alone.<\/p>\n\n\n\n

The IP dimension in Malaysia is relatively limited for most biosimilar categories. Most reference biologic patents are already expired or near expiration in Malaysia, given the country’s historical pharmaceutical patent framework and the 800-day approval lag that means most biosimilars are filed in Malaysia well after originator patent expiry. The primary IP concern in Malaysia for biosimilar developers is less about litigation risk and more about ensuring that the local partner’s activities comply with Malaysian pharmaceutical and IP regulations, particularly regarding product labeling, brand name use, and pharmacovigilance responsibilities.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways — Malaysia<\/strong><\/h3>\n\n\n\n

Malaysia has a mature, globally respected regulatory framework for biosimilars. The NPRA’s December 2023 guideline update aligns the country with WHO 2022 standards and provides clear procedural expectations for applicants. The commercial barrier to success is the public procurement system, not the regulatory pathway. Market entry strategies that do not explicitly address the tender process, local content requirements, and the structural price paradox will underperform regardless of the quality of the regulatory dossier. The 800-day approval lag is a structural challenge but one that companies can partially mitigate by filing in Malaysia earlier in the global rollout sequence, using the NPRA’s acceptance of EU clinical data to reduce the incremental submission burden.<\/p>\n\n\n\n

Investment Strategy — Malaysia<\/strong><\/h3>\n\n\n\n

Malaysia is not a standalone investment thesis for most biosimilar developers. It functions most effectively as part of a broader ASEAN market entry platform. Companies building an ASEAN biosimilar business should model Malaysian procurement revenue with high uncertainty bands given tender cycle timing variability and pricing unpredictability, and weight the strategic value of NPRA approval primarily in terms of its contribution to regional regulatory credibility rather than standalone revenue. Manufacturing joint ventures with Malaysian partners — particularly in the context of the Malaysian Investment Development Authority (MIDA) biotechnology incentive programs — can convert the local content challenge into a genuine cost and market access advantage. MIDA offers pioneer status tax exemptions and infrastructure subsidies for qualifying biopharmaceutical manufacturing investments, providing a financial rationale for local production investment that goes beyond procurement scoring alone.<\/p>\n\n\n\n

\n\n\n\n

Part V — Patent Intelligence: Navigating the Thicket<\/strong><\/h2>\n\n\n\n

The BPCIA ‘Patent Dance’ and Its Asian Equivalents<\/strong><\/h3>\n\n\n\n

The US Biologics Price Competition and Innovation Act (BPCIA) created a formal, multi-step process for pre-launch patent dispute resolution between biosimilar applicants and originators. The process — colloquially known as the ‘patent dance’ — involves mandatory exchange of the biosimilar’s regulatory application (the aBLA) with the originator, a defined period for the originator to identify patents it intends to assert, a further exchange period for the biosimilar developer to respond, and a litigation phase focused on a subset of the most commercially significant patents before launch.<\/p>\n\n\n\n

None of Japan, South Korea, or Malaysia has a procedure identical to the BPCIA patent dance. However, each has patent notification mechanisms for pharmaceutical products that trigger when a drug application references a registered originator product. In Japan, the PMDA requires a patent status declaration as part of the new drug application process, and the JPO provides an inter partes opposition process that can be used to challenge originator patents pre-launch. In Korea, the MFDS notification framework triggers a defined dispute resolution period when an originator’s registered patents are implicated by a biosimilar application. In Malaysia, the patent linkage system is less developed, but the Patents Act provides standard infringement and invalidity procedures before the Malaysian courts.<\/p>\n\n\n\n

For biosimilar developers operating globally, the practical implication is that the US patent dance experience — the specific patents asserted, the court rulings on their validity and scope, and the settlement terms — provides a useful, though imperfect, template for predicting patent risk in Asian markets. An originator patent invalidated in the US District Court for the District of Delaware is not automatically invalid in Japan or Korea, but the technical arguments that succeeded in US litigation often translate to the other jurisdictions’ patent systems, particularly when the invalidity argument is based on prior art that is global in nature.<\/p>\n\n\n\n

\n\n\n\n

Deconstructing the Originator Patent Thicket: Formulation, Process, Device<\/strong><\/h3>\n\n\n\n

The term ‘patent thicket’ describes the layered intellectual property portfolio that originator companies build around biologic products over their commercial lifetime. A typical large-molecule blockbuster carries 50 to 250 active patents at any given time, spread across multiple patent families in each major jurisdiction. The categories are predictable:<\/p>\n\n\n\n

Composition-of-matter patents covering the amino acid sequence, specific CDR sequences, or the protein’s 3D structure represent the foundation of the originator’s IP estate. These are typically the earliest-filed and earliest-expiring patents, and their expiration is the event that enables biosimilar development to begin. For a biologic first approved in the late 1990s or early 2000s, these patents will have expired or be expiring across major markets now.<\/p>\n\n\n\n

Formulation patents covering specific excipient systems, pH ranges, concentration levels, and stabilization agents can add three to seven years of effective exclusivity beyond composition-of-matter expiry. These patents are particularly active in Japan, where detailed formulation science is valued and where the PMDA’s quality emphasis makes formulation optimization an important commercial differentiator.<\/p>\n\n\n\n

Manufacturing process patents covering cell culture media compositions, feeding strategies, harvest conditions, specific chromatography resin types, or viral inactivation parameters are the most difficult to detect through public records because manufacturing processes are not disclosed in regulatory submissions. These patents require active intelligence gathering through patent database searches, freedom-to-operate opinion work, and, where necessary, experimental testing of whether a proposed manufacturing approach falls within or outside patent claims.<\/p>\n\n\n\n

Device patents covering auto-injectors, prefilled syringes, needle safety systems, and electronic injection monitoring devices have become the newest and most rapidly expanding category of evergreening IP. Companies including AbbVie (for Humira), Roche (for Herceptin SC and Perjeta), and Amgen (for Enbrel) have filed substantial device patent portfolios that biosimilar developers must navigate if they intend to offer a delivery device alongside their drug product.<\/p>\n\n\n\n

\n\n\n\n

Adalimumab as a Case Study in Aggressive Evergreening<\/strong><\/h3>\n\n\n\n

AbbVie’s Humira patent portfolio is the most-studied example of systematic biological product life cycle management. The strategy’s core components are now well-documented through US litigation discovery and are instructive for understanding how the next generation of biologic blockbusters will be managed as they approach their patent cliffs.<\/p>\n\n\n\n

AbbVie’s primary composition-of-matter patents covering the fully human anti-TNF antibody (adalimumab) expired in the US in 2016. AbbVie used the period from 2002 to 2016 to file and prosecute hundreds of additional patents covering the high-concentration subcutaneous formulation (100 mg\/mL), the citrate-free formulation that reduces injection site pain, specific methods of treating each of adalimumab’s approved indications, combination methods with methotrexate, the auto-injector device design, and manufacturing process improvements.<\/p>\n\n\n\n

By 2023, when Humira biosimilar entry finally occurred in the US, AbbVie had negotiated settlement agreements with all major biosimilar developers, including Amgen, AbbVie’s own subsidiary, Sandoz, and others, that specified US launch dates no earlier than January 2023. These settlements effectively converted AbbVie’s patent thicket into a time-limited market exclusivity extension worth an estimated $14 to $18 billion in additional US revenue between 2016 and 2023.<\/p>\n\n\n\n

In Japan, adalimumab biosimilars have been available since 2018, reflecting a different patent landscape — specifically, the earlier expiration of key Japanese patents and the absence of the same level of formulation patent coverage. The Japanese adalimumab market provides data on what post-entry competitive dynamics look like for this molecule class: price reductions of 30-40% from originator NHI price, multiple competing biosimilars from domestic and international developers, and continued prescribing of the originator in patient populations where prescribers have built long-term clinical relationships with the originator product.<\/p>\n\n\n\n

For the next wave of molecules — pembrolizumab, nivolumab, aflibercept, ustekinumab — analysts should assume that originator companies have studied the Humira precedent carefully and are constructing similar patent estates now, several years before the primary patent cliffs arrive. The window for biosimilar market entry timing in these molecules will be tighter and more litigation-intensive than it was for first-generation mAbs.<\/p>\n\n\n\n

\n\n\n\n

Freedom-to-Operate Analysis: The Non-Negotiable First Step<\/strong><\/h3>\n\n\n\n

A freedom-to-operate (FTO) analysis for a proposed biosimilar target must cover a minimum of four distinct patent categories: composition-of-matter (including all CDR sequence claims and antibody characterization claims), formulation (all excipient and concentration patents in each target market jurisdiction), manufacturing process (all upstream and downstream process patents identifiable through systematic patent database searching), and device (all delivery system patents for the specific administration route intended for the biosimilar).<\/p>\n\n\n\n

The FTO must be conducted jurisdiction by jurisdiction, because patent estates are national (or regional in the case of EPC patents) rather than global. A patent cleared in the US may be active in Japan, Korea, or Malaysia. Conversely, a Japanese patent may have no valid European counterpart. The FTO database for a single molecule in four jurisdictions (US, EU, Japan, Korea, Malaysia) can easily exceed 300 separate patent documents requiring evaluation.<\/p>\n\n\n\n

Platforms that aggregate patent data, litigation histories, regulatory approval records, and biosimilar activity for major biologic products — including DrugPatentWatch — reduce the time and cost of FTO analysis by providing pre-organized patent landscapes, litigation outcome histories, and biosimilar status tracking in a single interface. The practical value of these platforms is in their data completeness and currency: a patent that was filed six months ago and is not yet in commercial patent databases can be identified through specialized pharmaceutical patent aggregation services before it becomes an unexpected litigation risk.<\/p>\n\n\n\n

\n\n\n\n

Pembrolizumab and Nivolumab: The Next Patent Cliff<\/strong><\/h3>\n\n\n\n

Keytruda (pembrolizumab, Merck) and Opdivo (nivolumab, Bristol Myers Squibb) are the two dominant PD-1 checkpoint inhibitors, collectively generating more than $30 billion in global annual revenue as of 2024. Both products are approved across a large and growing number of oncology indications, making the extrapolation principle extremely valuable for biosimilar developers: a single clinical comparability program in one indication could support approval across potentially 20 or more approved uses.<\/p>\n\n\n\n

Core composition-of-matter patents for both molecules are expected to expire in major markets around 2028 to 2030, depending on jurisdiction and patent term extension status. Both Merck and BMS have filed extensive downstream patent portfolios covering specific formulations, manufacturing processes, combination methods (pembrolizumab plus chemotherapy, pembrolizumab plus axitinib, and many others), and patient selection methods based on PD-L1 expression levels.<\/p>\n\n\n\n

Korean companies are already positioning. Celltrion has publicly disclosed a pembrolizumab biosimilar development program. Samsung Bioepis has been less public about specific targets in the checkpoint inhibitor category, but its R&D investment trajectory strongly suggests active programs. Chinese companies including WuXi Biologics, CSPC, and others are also developing pembrolizumab biosimilars.<\/p>\n\n\n\n

The competitive landscape at pembrolizumab patent expiry will be substantially more crowded than it was at infliximab or trastuzumab expiry a decade ago, for two reasons. First, the commercial prize ($12 to $15 billion in global annual Keytruda revenue as of the expected expiry date) is large enough to justify simultaneous programs at ten or more companies. Second, the biosimilar development ecosystem has matured: more companies have the manufacturing capability, regulatory expertise, and capital access required to run a mAb biosimilar program than existed a decade ago.<\/p>\n\n\n\n

The IP battle for the pembrolizumab market will therefore be intense, multi-front, and high-stakes. Companies that complete their FTO analysis and file for approval earliest — with the strongest analytical comparability data packages and a litigation strategy that addresses the most commercially significant patents — will capture disproportionate share in the early years of market entry when price premiums are still meaningful.<\/p>\n\n\n\n

\n\n\n\n

Part VI — Cross-Market Strategy and the Regulatory Harmonization Horizon<\/strong><\/h2>\n\n\n\n

Country-Specific vs. Regional Platform Strategies<\/strong><\/h3>\n\n\n\n

The three markets examined here differ enough that a common regulatory submission package, while feasible at the analytical data core, requires meaningful local adaptation in the clinical section (for ethnicity justification), the pharmacovigilance section (local RMP requirements), and the market access strategy (country-specific reimbursement and procurement frameworks).<\/p>\n\n\n\n

A successful regional platform strategy shares the expensive parts — cell line development, analytical method development, bioreactor process development, comparative pharmacology studies — across the regional filing program, while building modular country-specific sections for regulatory submission that accommodate each agency’s specific requirements. The manufacturing comparability bridge between foreign-sourced reference product and locally registered comparator is the highest-effort common element required in all three markets and should be built once, comprehensively, as part of a global development program rather than as an afterthought in regional filings.<\/p>\n\n\n\n

The cost of a fully developed regional Asia strategy — PMDA, MFDS, and NPRA filings, along with all supporting studies — adds an estimated $15 to $25 million to a global biosimilar development program, depending on the analytical work required for bridging and the regulatory feedback cycles in each jurisdiction. That cost is recovered within the first 12 to 18 months of commercialization in Japan alone for any product in the oncology or autoimmune segment, making the regional program highly positive in NPV terms.<\/p>\n\n\n\n

\n\n\n\n

Biobetters and Device Innovation as Competitive Moats<\/strong><\/h3>\n\n\n\n

The Biobetter Strategic Logic<\/strong><\/h4>\n\n\n\n

A biobetter is a biological product engineered to be structurally similar to an approved biologic reference product but with one or more specific improvements: enhanced half-life through Fc engineering (YTE or LS mutations), improved potency through glycoengineering (enhanced afucosylation for higher ADCC), altered receptor selectivity, or new administration routes. Biobetters are not biosimilars and do not take the abbreviated biosimilar regulatory pathway — they require a new drug application with clinical data demonstrating the specific benefit claimed. However, they benefit from the established scientific and manufacturing knowledge base of the original biologic’s development, reducing early-stage discovery costs.<\/p>\n\n\n\n

The commercial rationale for a biobetter strategy is threefold. A biobetter creates new intellectual property — the engineered modifications are patentable, providing a new IP estate independent of the originator’s patent thicket. It competes on clinical differentiation rather than price, allowing premium pricing relative to both the originator and standard biosimilars. It differentiates a company’s commercial position in a market that is otherwise a commodity price competition, particularly as first-wave biosimilar categories mature and margins compress.<\/p>\n\n\n\n

Celltrion’s Remsima SC is the clearest near-term example: a subcutaneous infliximab formulation that offers patient convenience advantages over the IV infusion, created a new regulatory approval, and now generates premium pricing over IV biosimilar infliximab in markets where it is approved.<\/p>\n\n\n\n

Device Innovation in Japan<\/strong><\/h4>\n\n\n\n

The NIPRO\/Owen Mumford UniSafe safety syringe case in Japan demonstrates that in a high-quality-emphasis market, product design can be a decisive commercial differentiator. The UniSafe system, designed to prevent needlestick injuries through a passive automatic needle shield, achieved disproportionate market share in the first three months post-launch relative to competing biosimilars in the same therapeutic category.<\/p>\n\n\n\n

The specific commercial mechanisms were: clinical nurses and oncology pharmacists preferred the device for safety and ease of use, creating a grassroots adoption dynamic that did not require physician-level detailing; the product’s reliability in clinical use generated word-of-mouth recommendation within hospital systems that was faster-acting than traditional biosimilar adoption processes; and the device quality communicated indirectly that the manufacturing company prioritized product quality at all levels, building prescriber confidence in the underlying biologic.<\/p>\n\n\n\n

Device innovation requires additional investment — Owen Mumford devices are not commodity syringes, and the integration of a safety device into a biosimilar product requires device-compatibility studies, human factors engineering data, and regulatory submission of a drug-device combination product dossier. That investment, properly executed, generates a durable commercial moat in quality-sensitive markets like Japan.<\/p>\n\n\n\n

\n\n\n\n

AI-Accelerated Biomanufacturing and Its IP Implications<\/strong><\/h3>\n\n\n\n

The application of machine learning to biopharmaceutical manufacturing is moving from pilot programs to commercial-scale deployment at the leading Korean CDMOs and biosimilar developers. The primary applications in active use as of 2026 include: fed-batch feeding strategy optimization using reinforcement learning models trained on historical bioreactor performance data; real-time process monitoring and predictive control using multivariate statistical process control combined with neural network anomaly detection; glycosylation prediction from process parameter inputs, allowing manufacturers to tune the glycan profile in advance of the harvest rather than reactively adjusting post-analysis; and purification yield prediction from upstream culture performance metrics.<\/p>\n\n\n\n

The IP implications of AI-accelerated manufacturing are material and underappreciated. AI models trained on proprietary manufacturing data, particularly models that identify non-obvious process parameter relationships affecting product quality, may be patentable as novel process inventions. Samsung Biologics has filed patent applications covering AI-assisted bioprocess optimization methods, establishing a precedent for protecting AI-derived manufacturing intelligence as formal IP rather than merely as proprietary trade secret.<\/p>\n\n\n\n

For biosimilar developers, AI-generated process improvements that produce better batch-to-batch consistency, reduced aggregate levels, or more tightly controlled glycoform profiles serve a dual purpose: they improve product quality in ways that are relevant to regulatory comparability assessments, and they generate patentable process innovations that extend the company’s IP protection in the manufacturing domain independently of the product composition patents.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Harmonization: Where APAC is Heading<\/strong><\/h3>\n\n\n\n

The APAC regulatory harmonization project for biologics is advancing under multiple frameworks. The Asian Pharmaceutical Harmonization Network (APHN) coordinates regulatory harmonization among a subset of APAC agencies, including the MFDS and NPRA, on topics including biosimilar terminology, analytical method standards, and post-marketing pharmacovigilance requirements. The PMDA participates in ICH (International Council for Harmonisation) working groups that shape global standards, and Japan’s alignment with ICH Q12 (pharmaceutical lifecycle management) and Q14 (analytical procedure development) creates de facto convergence with EMA and FDA expectations.<\/p>\n\n\n\n

Full regulatory harmonization across Japan, Korea, and Malaysia — a single regional biosimilar application accepted by all three agencies simultaneously, in the way that a Centralized Procedure application covers all EU member states — is not achievable in the near term. The political, economic, and healthcare policy differences between a $90 billion developed market (Japan) and an $898 million developing market (Malaysia) preclude the institutional alignment required for a joint review process.<\/p>\n\n\n\n

The realistic near-term harmonization gains are incremental: expanded mutual reliance agreements allowing one agency to rely on another’s review conclusions for specific product categories; standardized data format requirements reducing reformatting effort in multi-country submissions; joint training programs building regulatory capacity in smaller APAC markets, reducing review times; and coordinated post-marketing safety signal detection sharing, improving pharmacovigilance efficiency without requiring common approval standards.<\/p>\n\n\n\n

\n\n\n\n

Comparative Data Tables<\/strong><\/h2>\n\n\n\n

Table 1: Biosimilars vs. Generics — Key Development Parameters<\/strong><\/p>\n\n\n\n

Parameter<\/th>Generic Drug<\/th>Biosimilar<\/th><\/tr><\/thead>
Active Ingredient<\/td>Chemically identical to reference<\/td>Highly similar, not identical, to reference biologic<\/td><\/tr>
Molecular Size<\/td>Small molecule (typically 180-500 Daltons)<\/td>Large protein (typically 20,000-150,000 Daltons)<\/td><\/tr>
Source<\/td>Chemical synthesis<\/td>Living cells (CHO, E. coli, yeast)<\/td><\/tr>
Manufacturing Process<\/td>Predictable chemical reactions; lot-to-lot identical<\/td>Complex biological process; inherent variability; ‘the process is the product’<\/td><\/tr>
Post-Translational Modifications<\/td>Not applicable<\/td>Glycosylation, disulfide bonds, deamidation; critical to function<\/td><\/tr>
Cold Chain Required<\/td>Generally not required<\/td>Generally required (2-8 degrees Celsius)<\/td><\/tr>
Development Timeline<\/td>2-3 years<\/td>7-9 years<\/td><\/tr>
Development Cost<\/td>$1-4 million<\/td>$100-250 million<\/td><\/tr>
Approval Standard<\/td>Bioequivalence (identical AUC and Cmax)<\/td>Totality of evidence: analytical, non-clinical, and clinical comparability<\/td><\/tr>
Automatic Substitution<\/td>Permitted in most markets<\/td>Jurisdiction-specific; generally requires specific designation or physician decision<\/td><\/tr>
Patent Landscape at Entry<\/td>Typically one composition-of-matter patent<\/td>Multiple patent families covering composition, formulation, process, device<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Table 2: Regulatory Framework Comparison — PMDA, MFDS, NPRA<\/strong><\/p>\n\n\n\n

Feature<\/th>Japan (PMDA)<\/th>South Korea (MFDS)<\/th>Malaysia (NPRA)<\/th><\/tr><\/thead>
First Biosimilar Guideline<\/td>2009<\/td>2009<\/td>2008<\/td><\/tr>
Harmonization Basis<\/td>ICH standards; PMDA-specific science-first emphasis<\/td>WHO, EMA, PMDA frameworks<\/td>EMA framework; updated to WHO 2022 in December 2023<\/td><\/tr>
Reference Product Requirement<\/td>Must be Japan-approved originator<\/td>Must be Korea-approved; foreign sourcing acceptable with bridging data<\/td>Must be Malaysia-registered innovator product<\/td><\/tr>
Acceptance of Foreign Clinical Data<\/td>Accepted with ethnic factor justification<\/td>Accepted as part of global development program<\/td>Accepted with population PK justification<\/td><\/tr>
Extrapolation<\/td>Permitted with scientific justification<\/td>Permitted with scientific justification<\/td>Permitted with scientific justification<\/td><\/tr>
Interchangeability Designation<\/td>No formal designation; prescriber decision<\/td>No formal designation; prescriber decision<\/td>Registered biosimilars considered clinically interchangeable for prescribing choice<\/td><\/tr>
Automatic Substitution<\/td>Not permitted<\/td>Not permitted<\/td>Explicitly prohibited; brand-name prescribing required<\/td><\/tr>
Post-Marketing Requirements<\/td>Mandatory RMP; immunogenicity monitoring; post-marketing safety studies<\/td>Four-year post-marketing surveillance; safety reporting<\/td>Mandatory RMP; PBRER; brand-name traceability in adverse event reports<\/td><\/tr>
Fast-Track Program<\/td>Standard review; no dedicated biosimilar fast track as of 2025<\/td>Dedicated fast-track program launching 2026<\/td>Accelerated review pathway for products with prior EMA\/FDA approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Table 3: Market Dynamics Comparison — Japan, South Korea, Malaysia<\/strong><\/p>\n\n\n\n

Parameter<\/th>Japan<\/th>South Korea<\/th>Malaysia<\/th><\/tr><\/thead>
Biosimilar Market Size (2024 est.)<\/td>Approximately $502 million<\/td>Approximately $531 million (2023)<\/td>$60-80 million (biosimilar-specific estimate)<\/td><\/tr>
Projected CAGR<\/td>9.3-22% depending on reimbursement reform scenario<\/td>22.5%<\/td>Approximately 4% (combined generics\/biosimilars)<\/td><\/tr>
Key Therapeutic Segments<\/td>Oncology (trastuzumab, bevacizumab, rituximab), autoimmune (infliximab, adalimumab, etanercept)<\/td>Oncology, autoimmune, ophthalmology<\/td>Oncology, autoimmune<\/td><\/tr>
Primary Commercial Incentive<\/td>DPC inpatient savings; government prescribing premium (1,500 yen\/prescription)<\/td>Government industrial policy; global export strategy<\/td>MOH procurement cost-reduction mandate<\/td><\/tr>
Primary Market Access Challenge<\/td>Co-pay paradox for high-cost outpatient biologics<\/td>Intense competition from state-backed domestic champions<\/td>800-day approval lag; opaque public procurement; Local Partner Advantage policy<\/td><\/tr>
Biosimilar Price Benchmark vs. Originator<\/td>Approximately 70% of originator at first NHI approval; further reductions in subsequent biennial revisions<\/td>Approximately 70-80% of originator at NHIS reimbursement<\/td>Set through tender process; variable<\/td><\/tr>
Originator Defense Strategy<\/td>Biosame launches; formulation evergreening; device innovation<\/td>Pipeline expansion into next-generation biologics; partnership pre-emption<\/td>Limited originator defense given market size<\/td><\/tr>
Top Commercial Entry Strategy<\/td>DPC hospital focus at launch; economic evidence for outpatient prescribers<\/td>Korean partner or niche category focus to avoid direct national champion competition<\/td>NPRA approval plus local partner for LPA qualification; government affairs investment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n\n\n\n

Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

How does interchangeability designation differ commercially across these three markets versus the US and EU?<\/strong><\/p>\n\n\n\n

The US FDA’s interchangeable designation is the only formal mechanism globally that enables automatic pharmacy-level substitution without prescriber involvement. This is the mechanism that drives 80-90% generic substitution rates in small-molecule markets, and its application to biosimilars has accelerated market share capture for interchangeable biosimilars against their reference products. None of Japan, South Korea, or Malaysia has an equivalent automatic substitution mechanism. In all three markets, prescribers must actively choose to prescribe the biosimilar by name, making physician education and medical affairs engagement the primary commercial leverage point rather than pharmacy channel management. The EU sits between these positions: EMA scientific consensus supports interchangeability, but member state policies on pharmacy substitution range from permissive to prohibitive. For Asia market modeling, assume that biosimilar market share growth is physician-led and therefore slower in the initial years than US models calibrated on interchangeable biosimilar penetration rates would project.<\/p>\n\n\n\n

What is the risk-adjusted ROI for a Japan market entry for a company currently holding EMA approval for a trastuzumab biosimilar?<\/strong><\/p>\n\n\n\n

The incremental cost of adding Japan to an existing EMA-approved trastuzumab biosimilar program is lower than for any other Asian market because the PMDA now accepts foreign clinical data with ethnic factor justification. The primary incremental costs are: PMDA submission preparation and agency interaction ($2-4 million), a Japan-specific pharmacokinetic bridging study if not already conducted ($3-6 million), and ongoing post-marketing RMP compliance ($1-2 million per year). The incremental Japan revenue opportunity at a conservative 10% market share of the Japanese trastuzumab biosimilar market is approximately $15-20 million annually at current NHI pricing. The payback period on the incremental Japan investment is roughly one year, and the ongoing Japan revenue contribution is high-margin given that Japan manufacturing and COGS are the same as for EU supply. The primary risk is delay due to PMDA review time and the formulation patent landscape specific to Japan, which may require additional design-around work.<\/p>\n\n\n\n

How should a non-Korean developer evaluate the ‘partner vs. compete directly’ decision for the South Korean market?<\/strong><\/p>\n\n\n\n

The decision turns on three questions. First, does the product target a category where Celltrion or Samsung Bioepis has an existing or pipeline product? If yes, direct competition requires either a meaningful quality advantage that commands premium pricing, a device or formulation innovation, or a cost structure capable of sustaining a price war with a company benefiting from $500+ million state-backed manufacturing infrastructure. Second, does the company have existing commercial infrastructure in Korea or a relationship with MFDS adequate to run an independent launch? If not, the time and cost of building those capabilities from zero is likely to exceed the revenue opportunity on most molecule categories. Third, is the value of Korea primarily as a revenue market or as a global regulatory credentialing platform? For companies whose primary Korea interest is regulatory, a licensing arrangement with a Korean partner provides MFDS approval and local commercial execution at lower capital commitment than a direct launch.<\/p>\n\n\n\n

What is the most important non-obvious risk in the Malaysian biosimilar market that analysts frequently underestimate?<\/strong><\/p>\n\n\n\n

The Local Partner Advantage scoring mechanism in public tenders is the most frequently underestimated risk. Most market analyses of Malaysia focus on the NPRA regulatory pathway, which is transparent and well-documented. The tender scoring system, which can override price competitiveness by a factor of two or more, is less visible in public documentation and is not adequately reflected in standard market size or addressable market calculations. A company that wins NPRA approval and bids competitively in a national tender without understanding the LPA scoring framework may lose the contract to a higher-priced local product without understanding why. The mitigation strategy is a local partnership or manufacturing presence, but this requires lead time of 18 to 36 months to establish, meaning it must be planned during the regulatory submission phase, not after tender loss.<\/p>\n\n\n\n

For a portfolio manager evaluating a company with both Samsung Bioepis exposure and Samsung Biologics CDMO exposure, how does the spinoff change the investment thesis?<\/strong><\/p>\n\n\n\n

The spinoff separates two revenue streams with fundamentally different risk profiles that were previously blended in a single equity vehicle. Samsung Biologics CDMO revenue is contract-based, diversified across multiple originator clients, and relatively stable given the multi-year nature of biologics manufacturing agreements. Its primary risk is new client concentration and capital expenditure timing for new facility builds. Samsung Bioepis revenue is product-based, concentrated on a biosimilar pipeline where any individual product’s revenue depends on competitive entry timing, patent litigation outcomes, and partner execution capability. The spinoff allows portfolio managers to separately size exposure to each risk profile: CDMO manufacturing is an infrastructure business with bond-like characteristics in stable periods; biosimilar development is a high-variance, event-driven business requiring different position sizing and monitoring. The combined entity previously obscured this distinction, likely leading to systematic mispricing of both components.<\/p>\n\n\n\n

How will the approval of pembrolizumab biosimilars change competitive dynamics in Asia, and which current players are best positioned?<\/strong><\/p>\n\n\n\n

Pembrolizumab biosimilar approvals in Korea, Japan, and Malaysia are expected in the 2029-2032 timeframe, depending on patent resolution timelines. The competitive dynamic will be materially different from first-generation mAb biosimilar categories for several reasons. Keytruda is approved across more than 40 tumor types and indications, making the extrapolation question more complex and the regulatory submission larger than for a single-indication or dual-indication product. The pricing and reimbursement dynamics in oncology immunotherapy are also more variable, since many pembrolizumab approvals are companion diagnostic-dependent (requiring PD-L1 expression testing), creating a segmented patient population with variable price sensitivity. Celltrion, given its existing oncology biosimilar infrastructure in Korea, Japan, and the US, is well-positioned to be a first-mover in the pembrolizumab category. Chinese developers with large oncology biosimilar programs are also investing, and the competitive launch period is expected to involve simultaneous market entry by five or more developers in major markets, compressing the early-entrant pricing premium window that was available for first-generation mAb biosimilars.<\/p>\n","protected":false},"excerpt":{"rendered":"

Why Asia is the New Biosimilar Battleground The Patent Cliff Meets a Demographic Supercycle The most consequential commercial event in […]<\/p>\n","protected":false},"author":1,"featured_media":34896,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-3016","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/3016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=3016"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/3016\/revisions"}],"predecessor-version":[{"id":37760,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/3016\/revisions\/37760"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34896"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=3016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=3016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=3016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}